(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2013 (13.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/084071 A3

(51) **International Patent Classification**:
A61K 39/08 (2006.01) *C07K 14/33* (2006.01)

(21) **International Application Number**:
PCT/IB2012/002955

(22) **International Filing Date**:
7 December 2012 (07.12.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
1121149.7 8 December 2011 (08.12.2011) GB
1217321.7 27 September 2012 (27.09.2012) GB

(71) **Applicant**: **NOVARTIS AG** [—/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) **Inventors**: **SCARSELLI, Maria**; c/o Novartis Vaccines and Diagnostic Srl, Via Fiorentina 1, 53100 Siena (IT). **PIZZA, Mariagrazia**; c/o Novartis Vaccines and Diagnostic Srl, Via Fiorentina 1, 53100 Siena (IT). **LEUZZI, Rosanna**; c/o Novartis Vaccines and Diagnostic Srl, Via Fiorentina 1, 53100 Siena (IT). **ARICO, Maria**; c/o Novartis Vaccines and Diagnostic Srl, Via Fiorentina 1, 53100 Siena (IT). **MARTINELLI, Manuele**; c/o Novartis Vaccines and Diagnostic Srl, Via Fiorentina 1, 53100 Siena (IT). **DOUCE, Gillian**; C/o University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow G12 8TA (GB).

(74) **Agent**: **MARSHALL, Cameron**; Carpmaels & Ransford, One Southampton Row, London WC1B 5HA (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
7 November 2013

(54) **Title**: CLOSTRIDIUM DIFFICILE TOXIN-BASED VACCINE

FIG. 11



(57) **Abstract**: The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB-GT antigen and a TcdA antigen or a ToxA-GT antigen and a TcdB antigen.

WO 2013/084071 A3